40,000 Shares in Establishment Labs Holdings Inc. (NASDAQ:ESTA) Purchased by Vestal Point Capital LP

Vestal Point Capital LP purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 40,000 shares of the company’s stock, valued at approximately $1,731,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Hood River Capital Management LLC purchased a new stake in Establishment Labs in the second quarter valued at approximately $43,000. Nkcfo LLC acquired a new stake in shares of Establishment Labs during the 2nd quarter worth $227,000. SG Americas Securities LLC purchased a new position in shares of Establishment Labs in the 2nd quarter worth $303,000. Black Swift Group LLC acquired a new position in Establishment Labs in the third quarter valued at $312,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Establishment Labs during the second quarter valued at about $373,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Price Performance

Shares of ESTA stock opened at $46.07 on Friday. Establishment Labs Holdings Inc. has a twelve month low of $22.05 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The firm has a fifty day simple moving average of $43.13 and a 200-day simple moving average of $44.99.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. cut their price objective on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Stephens reaffirmed an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. Citigroup increased their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, BTIG Research upped their price target on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $60.60.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.